Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) - 27/09/17
, M. Angelyn Bethel, MD b, Stephanie Gustavson, PhD c, Vivian P. Thompson, MPH a, Neha J. Pagidipati, MD, MPH a, John B. Buse, MD, PhD d, Juliana C. Chan, MD e, Nayyar Iqbal, MD c, Aldo P. Maggioni, MD f, Steve P. Marso, MD g, Peter Ohman, MD, PhD c, Neil Poulter, FMedSci h, Ambady Ramachandran, MD i, Bernard Zinman, MD j, Adrian F. Hernandez, MD, MHS a, Rury R. Holman, FRCP, FMedSc bAbstract |
Background |
EXSCEL is a randomized, double-blind, placebo-controlled trial examining the effect of exenatide once-weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in patients with type 2 diabetes mellitus (DM) and a wide range of cardiovascular (CV) risk.
Methods |
Patients were enrolled at 688 sites in 35 countries. We describe their baseline characteristics according to prior CV event status and compare patients with those enrolled in prior glucagon-like peptide-1 receptor agonist (GLP-1RA) outcomes trials.
Results |
Of a total of 14,752 participants randomized between June 2010 and September 2015, 6,788 (46.0%) patients were enrolled in Europe; 3,708 (25.1%), North America; 2,727 (18.5%), Latin America; and 1,529 (10.4%), Asia Pacific. Overall, 73% had at least one prior CV event (70% coronary artery disease, 24% peripheral arterial disease, 22% cerebrovascular disease). The median (IQR) age was 63 years (56, 69), 38% were female, median baseline HbA1c was 8.0% (7.3, 8.9) and 16% had a prior history of heart failure. Those without a prior CV event were younger with a shorter duration of diabetes and better renal function than those with at least one prior CV event. Compared with prior GLP-1RA trials, EXSCEL has a larger percentage of patients without a prior CV event and a notable percentage who were taking a dipeptidyl peptidase-4 inhibitor at baseline (15%).
Conclusions |
EXSCEL is one of the largest global GLP-1RA trials, evaluating the safety and efficacy of EQW with a broad patient population that may extend generalizability compared to prior GLP-1RA trials (ClinicalTrials.gov number, NCT01144338).
Le texte complet de cet article est disponible en PDF.Abbreviations : CV, EQW, EXSCEL, GLP-1RA, MACE, MI
Plan
| RCT# NCT01144338 |
|
| Frederick A Masoudi, MD, MSPH served as guest editor for this article. |
|
| Funding: The study is sponsored and funded by Amylin Pharmaceuticals Inc. (San Diego, CA), a wholly owned subsidiary of AstraZeneca (Gaithersburg, MD). Previous sponsors have included Eli Lilly and Company (Indianapolis, IN), and Bristol-Myers Squibb (Princeton, NJ). |
Vol 187
P. 1-9 - mai 2017 Retour au numéro
Article précédent
- Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
- M.J. Landray, L. Bowman, F. Chen, E. Sammons, J.C. Hopewell, K. Wallendszus, W. Stevens, E. Valdes-Marquez, S. Wiviott, C.P. Cannon, E. Braunwald, R. Collins, M.J. Landray (Writing Committtee)
- Determinants of operator radiation exposure during percutaneous coronary procedures
- Alessandro Sciahbasi, Stefano Rigattieri, Alessandro Sarandrea, Maria Cera, Cristian Di Russo, Silvio Fedele, Roberto Patrizi, Silvio Romano, Francesco Rocco Pugliese, Maria Penco, Samir B. Pancholy
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?